公开(公告)号：US20250031703A1

公开(公告)日：2025-01-30

申请号：US18797756

申请日：2024-08-08

Applicant: AUBURN UNIVERSITY

Inventor： Mark R. Liles ,  Joseph Kloepper

IPC: A01N63/22 ,  A01H3/00 ,  A23K10/18 ,  A23K20/163 ,  A23K50/80 ,  A61K31/7004 ,  A61K31/732 ,  A61K35/74 ,  A61K35/742 ,  A61K48/00 ,  A61P1/00

Abstract: To understand the growth-promoting and disease-inhibiting activities of plant growth-promoting rhizobacteria (PGPR) strains, the genomes of 12 Bacillus subtilis group strains with PGPR activity were sequenced and analyzed. These B. subtilis strains exhibited high genomic diversity, whereas the genomes of B. amyloliquefaciens strains (a member of the B. subtilis group) are highly conserved. A pairwise BLASTp matrix revealed that gene family similarity among Bacillus genomes ranges from 32-90%, with 2,839 genes within the core genome of B. amyloliquefaciens subsp. plantarum (now B. velezensis). Comparative genomic analyses of B. amyloliquefaciens strains identified genes that are linked with biological control and colonization of roots and/or leaves, including 73 genes uniquely associated with subsp. plantarum (now B. velezensis) strains that have predicted functions related to signaling, transportation, secondary metabolite production, and carbon source utilization. Although B. amyloliquefaciens (now B. velezensis) strains contain gene clusters that encode many different secondary metabolites, only polyketide biosynthetic clusters that encode difficidin and macrolactin are conserved within this subspecies. To evaluate their role in plant pathogen biocontrol, genes involved in secondary metabolite biosynthesis were deleted in B. amyloliquefaciens (now B. velezensis) strain, revealing that difficidin expression is critical in reducing the severity of disease, caused by Xanthomonas axonopodis pv. vesicatoria in tomato plants. This Example defines genomic features of PGPR strains and links them with biocontrol activity and with host colonization.

公开(公告)号：US20250025413A1

公开(公告)日：2025-01-23

申请号：US18433514

申请日：2024-02-06

Applicant: Ningbo Jildan Health Science and Technology Co., Ltd.

Inventor： Xiaofeng Hu ,  Dan Qiu ,  Qiuxia Qian ,  Xiaohui Lu ,  Lei Chen ,  Mingxia Li ,  Yingke Chen

IPC: A61K9/00 ,  A61K9/48 ,  A61K31/375 ,  A61K35/742

Abstract: The present disclosure provides a preparation method for liquid capsules and its application in nutritional gummies, belonging to the technical field of food processing. The preparation method for the liquid capsules provided by the present disclosure is as follows: hydrocolloid, a solvent and colorant are used to prepare a wall material, a functional substance, an additive and a dispersant are used to prepare a core material, the wall material is processed into capsule shell, and the core material is encapsulated in the capsule shell and then dried to obtain the liquid capsules. The present disclosure obtains the liquid capsules with good formability by adjusting and controlling the composition and ratio of the wall materials and core materials, which enables the liquid capsules to be effectively added to gummies syrup, thereby obtaining high-quality nutritional gummies with good stability.

公开(公告)号：US20250017985A1

公开(公告)日：2025-01-16

申请号：US18768920

申请日：2024-07-10

Applicant: Bio-Cat Microbials, LLC

Inventor： Jessica SPEARS ,  Laura Brutscher ,  Sean Garvey ,  James Farmar ,  Sebhat Gebrechristos ,  Christopher Schuler

IPC: A61K35/742 ,  A23K10/18 ,  A23K50/40 ,  A61K9/00 ,  A61K35/745 ,  A61K35/747 ,  A61K38/46 ,  A61K38/47 ,  A61K38/48 ,  A61P1/14

Abstract: A spore-forming Bacillus species, and more particularly, a Bacillus velezensis strain identified as BV379 is provided. Compositions comprising BV379 and methods of using the same are also provided.

公开(公告)号：US20240398878A1

公开(公告)日：2024-12-05

申请号：US18499450

申请日：2023-11-01

Applicant: CHAMBIO CO., LTD.

Inventor： Meei-Yn LIN ,  Hung-Pin CHIU ,  Yi-Heng CHIU

IPC: A61K35/747 ,  A61K35/742 ,  A61P11/00 ,  A61P29/00 ,  A61P31/14

Abstract: A method for preventing a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-associated disorder includes use of a composition containing live Bacillus coagulans CB85 which is deposited under the Budapest Treaty at the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) GmbH under an accession number DSM 33893, and heat-killed Lactobacillus plantarum CB102 which is deposited under the Budapest Treaty at the DSMZ GmbH under an accession number DSM 33894.

公开(公告)号：US12150965B2

公开(公告)日：2024-11-26

申请号：US17494897

申请日：2021-10-06

Applicant: Syngen Biotech Co., Ltd

Inventor： Wei-Jen Chen ,  Hui-Fang Chu ,  Yu-Lun Tsai ,  Shiuan-Huei Wu ,  Chi-Fai Chau

IPC: A61K35/742 ,  A23L33/135 ,  A61K35/744

Abstract: A combination of probiotics for improving body compositions includes Lacticaseibacillus paracasei S38 and Bacillus coagulans BC198. The combination of probiotics can be a medicine composition, a nutrient supplement, healthy food or a combination thereof. The applications of the combination of probiotics include weight loss, reduction of fat, abatement of appetite, production of butyric acid within intestinal tracts and an increased count of Akkermansia muciniphila or Ruminococcaceae inside intestines.

公开(公告)号：US20240376423A1

公开(公告)日：2024-11-14

申请号：US18293016

申请日：2022-07-06

Applicant: EVONIK OPERATIONS GMBH

Inventor： Thomas BERNGRUBER ,  Raoul DE GROOT ,  Yifei LANG ,  Frank VAN KUPPEVELD ,  Monika FLÜGEL ,  Stella MOLCK

IPC: C12N1/20 ,  A61K35/00 ,  A61K35/742 ,  C12R1/10 ,  C12R1/11 ,  C12R1/125

Abstract: The application relates to the identification and application of microorganisms which inhibit virus binding to viral target receptors by displaying decoy receptors on their surface, conferring competitive binding affinity to the viral particles.

公开(公告)号：US20240335487A1

公开(公告)日：2024-10-10

申请号：US18609015

申请日：2024-03-19

Applicant: Unique Biotech Limited

Inventor： Ratna Sudha Madempudi ,  Manoj Pandurang Dandekar ,  Manisurya Kumar Palepu ,  Srilakshmi Satya Satti

IPC: A61K35/747 ,  A61K31/198 ,  A61K35/742 ,  A61K35/745 ,  A61P25/24

CPC classification number: A61K35/747 ,  A61K31/198 ,  A61K35/742 ,  A61K35/745 ,  A61P25/24

Abstract: Multi-strain probiotic formulation for ameliorating and preventing symptoms of treatment resistant depression
The current invention more specifically relates to methods and compositions comprising a multi-strain probiotic formulation that can be used for alleviating symptoms of treatment-resistant depression in humans.
The multi-strain probiotic formulation disclosed herein for use as treatment for treatment-resistant depression symptoms comprises Bacillus coagulans, Lactobacillus plantarum, Lactobacillus rhamnosus, Bifidobacterium lactis, Bifidobacterium breve, and Bifidobacterium infantis. More specifically, the multi-strain probiotic formulation comprises Bacillus coagulans Unique IS-2, Lactobacillus plantarum UBLP-40, Lactobacillus rhamnosus UBLR-58, Bifidobacterium lactis UBBLa-70, Bifidobacterium breve UBBr-01, and Bifidobacterium infantis UBBI-01.

公开(公告)号：US20240307464A1

公开(公告)日：2024-09-19

申请号：US18627241

申请日：2024-04-04

Applicant: Novozymes A/S

Inventor： Kiran Krishnan ,  Dale M. KRIZ ,  Thomas F. BAYNE

IPC: A61K35/744 ,  A61K9/00 ,  A61K35/742 ,  A61P1/14 ,  A61P31/04

CPC classification number: A61K35/744 ,  A61K9/0053 ,  A61K35/742 ,  A61P1/14 ,  A61P31/04

Abstract: The present invention is directed to methods of administering a probiotic composition including Bacillus subtilis, Bacillus licheniformis, and Pediococcus acidilactici to dogs to decrease endotoxemia and improve the digestive process, and related methods.

公开(公告)号：US20240307462A1

公开(公告)日：2024-09-19

申请号：US18676470

申请日：2024-05-28

Applicant: The University of Tokyo

Inventor： Kenya Honda ,  Koji Atarashi ,  Kikuji Itoh ,  Takeshi Tanoue

IPC: A61K35/742 ,  A01K67/0275 ,  A61K9/00 ,  A61K9/48 ,  A61K35/00 ,  A61K35/74 ,  A61K39/00 ,  A61K39/08 ,  A61K39/39 ,  A61K45/00 ,  A61K45/06 ,  C12Q1/689 ,  G01N33/50

CPC classification number: A61K35/742 ,  A01K67/0275 ,  A61K9/0053 ,  A61K9/48 ,  A61K35/74 ,  A61K39/0008 ,  A61K39/08 ,  A61K39/39 ,  A61K45/00 ,  A61K45/06 ,  C12Q1/689 ,  G01N33/505 ,  A01K2267/0325 ,  A61K35/00 ,  A61K2039/52 ,  A61K2039/542 ,  A61K2039/55594 ,  A61K2039/57 ,  C12Q2600/158 ,  G01N2333/33 ,  G01N2500/10

Abstract: It was found that bacteria belonging to the genus Clostridium induce accumulation of regulatory T cells (Treg cells) in the colon. Moreover, the present inventors found that regulatory T cells (Treg cells) induced by from these bacteria suppressed proliferation of effector T-cells. From these findings, the present inventors found that the use of bacteria belonging to the genus Clostridium or a physiologically active substance derived therefrom made it possible to induce proliferation or accumulation of regulatory T cells (Treg cells), and further to suppress immune functions.

公开(公告)号：US20240307461A1

公开(公告)日：2024-09-19

申请号：US18430704

申请日：2024-02-02

Applicant: Unique Biotech Limited

Inventor： Ratna Sudha Madempudi ,  Jayanthi Neelamraju

IPC: A61K35/742 ,  A61P1/00

CPC classification number: A61K35/742 ,  A61P1/00

Abstract: The current invention discloses the method of treating, preventing and/or ameliorating Inflammatory Bowel Disease in patients by administering a probiotic composition comprising Bacillus clausii. The current invention discloses a method for, prevention and/or treatment, and amelioration of symptoms of Inflammatory Bowel Disease by use of Bacillus clausii, which modulates the microbiome in the gastro-intestinal tract and decreases inflammation in the patients.